The global anti-aging market is worth billions of dollars with significant growth potential. Here’s a list of some of the anti-aging stocks looking to capitalize on that growth.
As the global population continues to get older, the popularity of anti-aging stocks is also rising thanks to advancements in technology and research on human longevity.
The desire to increase life quality and expectancy drives the top anti-aging stocks in the life science space as they pursue technologies and therapies aimed at slowing the aging process and preserving health.
According to market research firm IMARC, the global anti-aging industry is projected to be worth a staggering US$93.1 billion by 2027, up from US$62.6 billion in 2021; it is seen growing at a compound annual growth rate of 6.74 percent during the forecast period, even with the impact of COVID-19.
The research firm attributes this growth to new anti-aging treatments and products brought about by advancements in technology and increased investment in research and development, as well as higher demand for anti-aging products and devices from both young and older consumers.
Below is a brief overview of five anti-aging stocks on the NYSE and NASDAQ. Only companies with market caps between US$50 million and US$500 million were considered for the list. All figures were current as of July 28, 2022.
Market cap: US$480.29 million
First on this list of anti-aging stocks is commercial biopharma company Radius Health. The company’s focus is on unmet medical needs targeting bone health, neurological orphan diseases and oncology.
The lead product in its pipeline is its TYMLOS injection, whose generic name abaloparatide; it is an osteoporosis treatment for postmenopausal women that has been approved by the US Food and Drug Administration. Radius’ pipeline also includes an investigational abaloparatide injection for potential use in treating osteoporosis in men, as well as the investigational drug elacestrant as a potential breast cancer treatment.
In late June 2022, Radius Health agreed to a US$890 million buyout from investment firms Gurnet Point Capital and Patient Square Capital. After the sale is finalized, the company will become private.
Market cap: US$382.28 million
Clinical-stage gene therapy company MeiraGTx Holdings is leveraging its gene therapy manufacturing capabilities and transformative gene-regulation platform to develop treatments for patients with serious conditions, such as age-related diseases. The company’s pipeline features six clinical trial programs, including a few that are targeting degenerative ocular diseases and Parkinson’s disease.
The company filed an investigational new drug application for its potential Parkinson’s disease treatment in May 2022 with material manufactured in its cGMP facility in London, England.
Market cap: US$371.48 million
Aerie Pharmaceuticals is developing and commercializing therapies targeting eye diseases and conditions, including open-angle glaucoma, dry eye, diabetic macular edema and wet age-related macular degeneration.
The ophthalmic pharmaceutical company’s drug portfolio includes approved products generating revenue. Aerie’s Q1 2022 financial results include US$29.8 million in total glaucoma franchise net product revenues, up 30 percent compared to the same quarter the previous year. The company’s full-year 2022 guidance for its glaucoma franchise net product revenues is a range of US$130 million to US$140 million.
Market cap: US$274.95 million
Lineage Cell Therapeutics works in the fields of regenerative medicine, human embryonic stem cell technology and induced pluripotent stem cell technology. It develops therapies that are based on stem cell biology and are intended to rebuild cell and tissue function lost due to degenerative diseases and injury.
The company’s stem cell programs include: OpRegen, which is a cell-replacement therapy in a Phase 2a clinical trial to treat advanced dry age-related macular degeneration; OPC1 for acute spinal cord injuries, which has completed Phase 2a clinical trials and is now in the planning phases for Phase 2b/3 trials; and VAC2, which is in a Phase 1 clinical trial in patients with non-small-cell lung cancer.
Market cap: US$223.97 million
Acumen Pharmaceuticals is leveraging its expertise in amyloid-beta oligomers to develop Alzheimer's disease treatments. The clinical-stage biopharmaceutical company’s lead therapeutic candidate, ACU193, is an anti-amyloid-beta oligomer (ABO) monoclonal antibody. Toxic ABOs are early and persistent drivers of the neurodegeneration that leads to Alzheimer’s. ACU193 is designed to prevent toxic ABOs from damaging neuronal function.
Acumen expects to publish topline results from its Phase 1 clinical trial of ACU193 for patients with early Alzheimer’s disease in the first half of 2023. If results prove positive, the company will consider initiating a Phase 2/3 clinical trial.
This is an updated version of an article originally published by the Investing News Network in 2017.
Don’t forget to follow us @INN_LifeScience for real-time news updates.
Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.
- Genetics Stocks: 5 Biggest Companies in 2022 ›
- 10 Top Stem Cell Companies on the NASDAQ ›
- 4 Private Longevity Research Companies to Watch | INN - Investing News ›
- 3 Alzheimer’s Disease Treatment Stocks on the NASDAQ | INN ›
- 5 Gene Therapy Stocks for Investors | INN ›
- Plant-based Food Stocks: 10 Biggest Companies in 2022 ›
- 5 Top Genetic Testing Stocks ›